NBC News USA reports…
The Meals and Drug Administration and the Federal Trade Commission sent warning letters Tuesday to 3 firms that industry CBD goods, saying the firms are producing false claims about treating ailments such as cancer and Alzheimer’s.
The agencies claim that 3 firms — Nutra Pure, PotNetwork Holdings, and Sophisticated Spine and Discomfort — are falsely marketing the effectiveness of supplements that include cannabidiol, typically recognized as CBD. The goods are marketed beneath names such as “ Hemp Oil,” “ CBD Softgels,” “ CBD for Dogs,” “Liquid Gold Gummies,” and “ CBD Oil.” 1 organization in specific — Nutra Pure — advertises that scientific study supports their claims that their CBD item is an efficient anti-seizure medication.
“According to their ads, the goods can properly treat ailments, such as cancer, Alzheimer’s illness, fibromyalgia, and ‘neuropsychiatric problems,’” the FDA and FTC mentioned jointly in a statement.
The letters instruct the firms to notify the FTC inside 15 days of receipt of the letter of the particular action taken to address the agency’s issues.
This is the initial time the FDA and FTC have issued a joint warning letter collectively, but it is not the initial time the firms have cracked down on unfounded CBD claims. In 2017, the FDA warned 4 firms to quit producing unproven claims that their cannabis-primarily based hemp and marijuana goods could treat cancer. Final year, the FDA issued a statement banning CBD in meals goods.
THE PRESS RELEASE
FTC Joins FDA in Sending Warning Letters to Corporations Marketing and Promoting Goods Containing Cannabidiol ( CBD) Claiming to Treat Alzheimer’s, Cancer, and Other Ailments
As component of its ongoing efforts to assure that dietary supplements and other wellness-associated goods are advertised truthfully, and that efficacy claims produced for such goods are supported by competent and dependable scientific proof, the Federal Trade Commission joined the U.S. Meals and Drug Administration (FDA) in sending warning letters to 3 firms advertising goods containing cannabidiol to treat and remedy a wide variety of severe ailments and situations.
According to the letters, which the agencies sent to Nutra Pure LLC; PotNetwork Holdings, Inc.; and Advanced Spine and Pain, LLC (d/b/a Relievus), the FTC believes that the advertised products may violate the FTC Act by making false or unsubstantiated health claims.
The three companies advertise a range of supplements they say contain cannabidiol, commonly known as CBD, such as “ Hemp Oil,” “ CBD Softgels,” “Liquid Gold Gummies,” and “ CBD Oil.” According to their advertisements, the products can effectively treat diseases, including cancer, Alzheimer’s disease, fibromyalgia, and “neuropsychiatric disorders.” In addition, ads for products sold by Nutra Pure, LLC claim that, “Science also shows that CBD has anti-emetic, anti-convulsive, anti-inflammatory and analgesic properties,” and that, “ CBD is a viable option for minimizing these effects within the brain.”
The joint FTC and FDA letters warn the companies about the potential legal consequences of making unsupported health and efficacy claims in advertising, and strongly urge them to review all product claims they are making to ensure they are supported by competent and reliable scientific evidence. The letters instruct the companies to notify the FTC within 15 days of receipt of the letter of the specific action taken to address the agency’s concerns.
The FDA sent the warning letters, which the FTC co-signed, on March 28, 2019. (The staff contact is Richard Cleland, FTC’s Bureau of Consumer Protection, 202-326-3088.)
The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about consumer topics and file a consumer complaint online or by calling 1-877-FTC-HELP (382-4357). Like the FTC on Facebook, follow us on Twitter, study our blogs, and subscribe to press releases for the most recent FTC news and sources.